Citable filing context
A's research view summarizes recent SEC filing context, starting with debt_offering from Jun 25, 2026.
| Filed | Item | Context |
|---|---|---|
| Jun 25, 2026 | debt_offering | Agilent Technologies sold $600 million of 4.900% Senior Notes due 2032 in a private placement. |
| May 27, 2026 | earnings | Agilent reported Q2 2026 revenue of $1.83 billion and raised its full-year 2026 revenue guidance. |
| May 4, 2026 | management_change | Agilent Technologies appointed Michael Buckner as Chief Legal Officer, effective May 4, 2026. |
| May 27, 2026 | Guidance: non_gaap_eps | 6.00 to 6.10 |
| May 27, 2026 | Guidance: non_gaap_eps | 1.48 to 1.50 |
| May 27, 2026 | Guidance: revenue | 1830.00 to 1850.00 |
| Jun 1, 2026 | mda_quarterly | Agilent Technologies reported net revenue of $3.633 billion for the six months ended April 30, 2026, an 8% increase year-over-year, with net income rising to $644 million. Growth was broad across segments, led by Applied Markets (up 10%) and Life Sciences and Diagnostics Markets (up 8%). Key drivers included liquid chromatography, spectroscopy, and the Agilent Advanced Therapeutics CDMO business, with particular strength in pharmaceutical, chemical, and advanced materials markets, offsetting declines in academia and government spending. The company is expanding its Life Sciences and Diagnostics portfolio through the pending $950 million cash acquisition of Biocare. To enhance operating margins, Agilent is executing a restructuring plan targeting $90 million to $95 million in annual cost reductions. Financial risks include inflationary pressures from Middle East geopolitical tensions and evolving trade dynamics, though the company is seeking refunds for IEEPA tariffs following a Supreme Court invalidation. Capital expenditures are projected at $450 million for the year, primarily to expand advanced therapeutics manufacturing capacity in Frederick, Colorado. Shareholder returns remain a priority, evidenced by a $2 billion share repurchase program and consistent quarterly dividends. |
| Mar 3, 2026 | mda_quarterly | Agilent Technologies reported net revenue of $1.798 billion for the quarter ended January 31, 2026, a 7% increase year-over-year, though net income declined to $305 million. Growth was distributed across all segments, led by Agilent CrossLab (+9%) through strong demand for repair, maintenance, and consumables. Life Sciences and Diagnostics Markets grew 5%, driven by the BIOVECTRA CDMO business, liquid chromatography, and pathology solutions, while Applied Markets grew 7%, primarily in the chemicals and advanced materials sectors. Operating margin contracted by 3 percentage points to 19.7%, pressured by increased tariffs, restructuring expenses, and higher corporate infrastructure costs. To protect margins, the company is implementing supply chain optimization and targeted pricing. Additionally, the FY25 restructuring plan targets $90 million to $95 million in annual cost reductions. Capital expenditures are projected at $500 million for the fiscal year, centered on expanding nucleic acid therapeutics manufacturing capacity in Frederick, Colorado. Cash provided by operations decreased to $268 million. The company remains active in returning capital, spending $152 million on share repurchases under its $2 billion authorization and paying quarterly dividends of $0.255 per share. |
Source: SEC EDGAR filing text and events; period Jun 25, 2026; filed Jun 25, 2026.
A company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.